News >

Role of PARP Inhibitors in Breast Cancer Continues to Be Refined

Danielle Bucco
Published: Thursday, Apr 19, 2018

Nadine M. Tung, MD

Nadine M. Tung, MD
PARP inhibitors, having shown success in ovarian cancer, have finally made it to the treatment paradigm for patients with BRCA-positive breast cancers, explains Nadine M. Tung, MD.

-positive breast cancer and the importance of genetic testing.

OncLive: What is the current treatment landscape of PARP inhibitors for patients with breast cancer?

Tung: The newest development is the OlympiAD trial and the FDA approval of olaparib for patients with germline BRCA mutations who have metastatic, HER2-negative breast cancer. The FDA approved use of olaparib in January 2018, so that is available now for patients who have metastatic HER2-negative breast cancer. Those patients also have a germline BRCA1/2 mutation and have seen chemotherapy at some point—either in the initial setting, adjuvant, neoadjuvant, or metastatic setting.

What other PARP inhibitors are being investigated?

Firstly, the OlympiAD trial investigated olaparib compared with nonplatinum standard chemotherapy. Olaparib led to a significant improvement in PFS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication